Similar articles

• Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.

  Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Athyros VG, Mikhailidis DP. Karagiannis A, et al. Expert Opin Pharmacother. 2008 Mar;9(4):509-15. doi: 10.1517/14656566.9.4.509. Expert Opin Pharmacother. 2008. PMID: 18312153 Clinical Trial.
• [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].

  Derer W, Dechend R, Müller DN. Derer W, et al. MMW Fortschr Med. 2010 Feb 11;152(6):48-9. doi: 10.1007/BF03366066. MMW Fortschr Med. 2010. PMID: 20302183 Review. German. No abstract available.
• Mineralocorticoid receptor antagonists and endothelial function.

  Maron BA, Leopold JA. Maron BA, et al. Curr Opin Investig Drugs. 2008 Sep;9(9):963-9. Curr Opin Investig Drugs. 2008. PMID: 18729003 Free PMC article. Review.
• Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.

  Matsuda Y, Kawate H, Matsuzaki C, Sakamoto R, Shibue K, Ohnaka K, Anzai K, Nomura M, Takayanagi R. Matsuda Y, et al. Endocr J. 2016;63(3):249-55. doi: 10.1507/endocrj.EJ15-0362. Epub 2015 Dec 25. Endocr J. 2016. PMID: 26727302
• Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.

  Pelliccia F, Rosano G, Patti G, Volterrani M, Greco C, Gaudio C. Pelliccia F, et al. Int J Cardiol. 2015 Dec 1;200:8-11. doi: 10.1016/j.ijcard.2014.10.150. Epub 2014 Oct 24. Int J Cardiol. 2015. PMID: 25466561 Review.